I share this opinion: In addition I have a serious question:
Because of Copaxone's patent issues, TEVA is trading at an attractive level of $40, which is well below its all time high of $63/share. I believe that Teva Pharmaceutical's diverse group of branded products, impressive pipeline, successful generic business, good dividend, and attractive entry point make this a very good time to open or add to a position in Tev
My question is how much revenue, and profit per share is realistic to project about Plan B?
I bought more yesterday, and got smacked down!